Does Insurance Cover Compounded GLP-1 Medications?

Quick answer

Most health plans do not cover compounded GLP-1 medications, and compounded semaglutide is not covered by insurance on nearly any commercial, Medicare or Medicaid plan. As of September 2026, a compounded preparation is not an FDA-approved drug product, and plans pay on formulary terms built around approved products, so compounded semaglutide and compounded tirzepatide usually sit outside the pharmacy benefit entirely. The one federal program paying a set amount for GLP-1 treatment right now, the Medicare GLP-1 Bridge, charges eligible enrollees a $50 monthly copay as of September 2026 and lists only FDA-approved products. For nearly everyone using a compounded GLP-1, the number that matters is a cash price, not a copay.

Compounded medications are not FDA-approved as final products. That single fact drives most of what follows, and it is worth understanding rather than simply accepting, because the exceptions and the appeal routes only make sense once you can see the machinery underneath.

Why coverage is rare, and the one route worth trying anyway

People usually read a coverage denial as a judgment about them: their body mass index, their documentation, their plan being stingy. For compounded GLP-1 medications, it is rarely that. The preparation never entered the payment system in the first place.

There is still a route worth walking, and it has conditions rather than a maybe. A health plan that provides essential health benefits must, under 45 CFR 156.122(c), have a process letting you, your designee or your prescriber request access to a clinically appropriate drug the plan does not otherwise cover, and plans subject to 45 CFR 147.136 must offer an internal appeal and then an independent external review after a denial, each with deadlines the plan has to meet. The arguments that carry a formulary exception are the same three every time: that the drug is medically necessary for your documented condition, that you have tried and failed or cannot tolerate the FDA-approved alternatives on the formulary, and that your prescriber will put both in writing. Be clear-eyed about the odds for a compounded preparation specifically: the approval hook described below is the reason most of these end in a no. Even then, a written no is what lets you compare your real options honestly.

Coverage at a glance, by medication and plan type

Why a plan pays for one drug and not another

Three reasons stack, and each one is checkable.

One: the approval hook. Coverage definitions are written around FDA approval. For Medicare Part D, 42 U.S.C. 1395w-102(e)(1)(A) defines a covered Part D drug by pointing at 42 U.S.C. 1396r-8(k)(2)(A), and clause (i) of that definition describes a drug "which is approved for safety and effectiveness as a prescription drug under section 505" of the Federal Food, Drug, and Cosmetic Act. Commercial formularies are built on the same approved-product architecture. The FDA states the other half of the equation in its own words: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." On the same page, FDA separates compounded drugs from generics, noting a generic drug is approved under section 505(j) and meets all the requirements of that section, while a compounded drug is not approved by FDA.

Two: an identifier is not coverage. You may read that compounded drugs cannot be billed because they have no National Drug Code. That is not accurate, and the accurate version is stronger. FDA's own NDC Directory page states that the directory "contains compounded drug products reported and the assigned NDC within the last two years," and that outsourcing facilities may elect to assign NDCs to their products. The same page then closes the door: "Inclusion in the NDC Directory does not mean a product is covered or eligible for reimbursement by Medicare, Medicaid or other payers." A number in a database is a listing, not a benefit.

Three: many plans exclude weight-loss drugs outright. This is the one that surprises people, because it applies to brand products too. Federal law lets Medicaid programs exclude or restrict an entire category, and 42 U.S.C. 1396r-8(d)(2) lists what may be excluded. The first item reads: "Agents when used for anorexia, weight loss, or weight gain." Many employer plans write the same exclusion into their own documents. If your plan is in that group, the brand versus compounded question does not decide coverage, because nothing in the category is covered.

Does Medicare cover compounded GLP-1 medications?

No, and the statute closes the route twice.

The Part D exclusion is a cross-reference, which is why the words are easy to misquote. 42 U.S.C. 1395w-102(e)(2)(A) states that the term covered Part D drug "does not include drugs or classes of drugs, or their medical uses, which may be excluded from coverage or otherwise restricted under section 1396r-8(d)(2) of this title," with narrow carve-outs for smoking cessation agents, for benzodiazepines, and for barbiturates used in treating epilepsy, cancer or a chronic mental health disorder. The phrase weight loss does not appear in that Part D section at all. It appears one step down the chain, at 42 U.S.C. 1396r-8(d)(2)(A): "Agents when used for anorexia, weight loss, or weight gain." Read the two together and the exclusion is plain. Read either alone and you will quote it wrong.

Separately, the covered Part D drug definition runs through the section 505 approval requirement described above, which a compounded preparation does not meet. So even a Part D plan that wanted to pay has no category to pay it under.

What did change is what Medicare does with approved products. Medicare.gov now describes access to certain GLP-1 drugs for people who meet listed criteria, including a body mass index of 35 or higher, or 30 or higher with diastolic heart failure, uncontrolled high blood pressure or chronic kidney disease at stage 3a or higher, or 27 or higher with prediabetes, a previous heart attack or stroke, or peripheral artery disease with symptoms. Those criteria govern approved products. For the brand side in detail, see our Medicare explainer at /blog/does-medicare-cover-wegovy-ozempic-glp1.

What the Medicare GLP-1 Bridge does, and what it does not do

This is the most misread program in the category right now, so here it is only as the government prints it.

CMS describes the Medicare GLP-1 Bridge as "a short-term demonstration run by CMS that will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027." The CMS page states that the program operates outside the Part D benefit's coverage and payment flow, that eligible beneficiaries have a $50 copay as of September 2026, that the Part D deductible does not apply, that no part of that copay counts toward the beneficiary's true out-of-pocket (TrOOP) costs, and that no low-income subsidy is provided for low-income subsidy beneficiaries. The CMS press release announcing the launch is dated July 1, 2026 and states that eligible Medicare beneficiaries may get certain GLP-1 medications for $50 per month, as of September 2026.

Medicare.gov names the covered products: Foundayo tablet, Wegovy injection or tablet, and Zepbound KwikPen, with the note that the program does not cover single-dose Zepbound vials or pens, as of September 2026. Who qualifies, which forms are left out and how the prior authorization works are covered in our Medicare guide at /blog/does-medicare-cover-wegovy-ozempic-glp1. The only fact that matters here is the product list.

Every product named in that program is an FDA-approved product. The Bridge is not a route to a compounded preparation, and no compounded preparation reaches that copay.

Does Medicaid cover it? Check your own state, and check the date

Medicaid is not one program. It is a federal framework with state decisions inside it, and the weight management category is explicitly optional. Pennsylvania's Department of Human Services says so in its own bulletin: "Coverage of drugs for weight loss is an optional benefit for Medicaid programs. See 42 U.S.C. 1396r-8(d)(2)(A)."

Three states, three documents, all effective January 1, 2026:

• Pennsylvania. The Medical Assistance Bulletin issued November 24, 2025 states that effective January 1, 2026, drugs containing a GLP-1 receptor agonist will not be covered for the treatment of overweight and obesity, that such drugs will continue to be covered for all other medically accepted indications with a prior authorization, and that Saxenda will no longer be covered for any indication.
• Michigan. MDHHS numbered letter L 25-73, dated December 8, 2025, states that effective for dates of service on or after January 1, 2026, coverage of GLP-1 medications prescribed solely to treat obesity will be reduced under Public Act 22 of 2025, and that coverage will require the patient to be "classified as morbidly obese" and be "contingent on documented failure of all other clinically appropriate weight-loss interventions," including a trial and failure of preferred anti-obesity agents on the state list.
• North Carolina. The NC Medicaid Preferred Drug List effective January 1, 2026, revised December 10, 2025, lists Wegovy Pen as Preferred, with Saxenda Pen and Zepbound Pen as Non-Preferred in the same class.

Notice what none of the three documents contains: a compounded preparation. State programs pay against a published list of products, and compounded preparations are not on those lists. For the state by state picture, see /blog/does-medicaid-cover-compounded-glp1.

Commercial plans: prior authorization, exception requests, and appeals

For an approved product, coverage usually is not a yes or no so much as a process. Plans that cover a GLP-1 for weight management commonly require prior authorization first, and the public criteria show what that asks for. Medicare.gov requires the prescriber to send the prescription and, when requested, complete a prior authorization. Michigan Medicaid requires the patient to be classified as morbidly obese and makes coverage contingent on documented failure of all other clinically appropriate weight-loss interventions. The request can end in a denial.

If the drug is not on the formulary at all, the tool is a formulary exception. The Washington State Office of the Insurance Commissioner describes the process for that state and gives concrete timings: the insurer must respond within three days unless it needs more information from your provider, and within one day if the request is urgent. The same page states that if you or your provider do not hear back inside the period, the request is automatically approved, and that if a medication keeps you stable, the insurer must let you keep taking it until a decision is made. Rules and deadlines vary by state and plan type, so find your own state insurance department page rather than assuming Washington's timings apply to you.

A denial is not the end of the sentence. Under 45 CFR 147.136, the notice must contain "information sufficient to identify the claim involved (including the date of service, the health care provider, the claim amount (if applicable), and a statement describing the availability, upon request, of the diagnosis code and its corresponding meaning" and the treatment code and its meaning. The rule also requires the plan to provide those codes on request as soon as practicable, and states the plan must not treat that request by itself as a request for an appeal. In plain terms: you are entitled to know exactly what was denied and on what coded basis, and asking does not burn your appeal.

After that come two steps. HealthCare.gov describes an internal appeal, then an independent external review, and puts the point sharply: "External review means that the insurance company no longer gets the final say over whether to pay a claim." Its external review page states you must file a written request within 4 months after the date you receive the denial notice, and that the insurer is required by law to accept the external reviewer's decision. Those deadlines are real, so diary them the day the letter arrives.

Can you use an HSA or FSA?

This is a tax question, not a coverage question, and keeping the two apart saves a lot of confusion.

IRS Publication 502 defines medical expenses as "the costs of diagnosis, cure, mitigation, treatment, or prevention of disease and for the purpose of affecting any part or function of the body," and on medicines it states: "You can include in medical expenses amounts you pay for prescribed medicines and drugs. A prescribed drug is one that requires a prescription by a doctor for its use by an individual." It adds that except for insulin, you cannot include amounts paid for a drug that is not prescribed. Publication 969, which covers health savings accounts and health flexible spending arrangements, ties the term to the same place: "Qualified medical expenses are those specified in the plan that would generally qualify for the medical and dental expenses deduction."

Two cautions. Your plan document and your account administrator set the substantiation rules, and an administrator may ask for an itemized receipt or a letter of medical necessity before or after the charge. And paying with pre-tax dollars reduces what the treatment costs you by roughly your marginal tax rate; it does not mean anything was covered, and it is not a workaround for a plan exclusion.

What to ask your plan, and how to get it in writing

Call the member services number on your card, ask these in order, and write the answers down with the date, the representative's name and a reference number for the call.

1. Does my plan cover any GLP-1 medication for weight management, or only for its approved diabetes use?
2. Please send me the formulary document itself, and the prior authorization criteria sheet for this drug class.
3. Does my deductible apply to this medication, and what do I pay out of pocket after I have met it?
4. What is my copay or coinsurance on the covered product, at which pharmacy tier?
5. Are compounded medications reimbursable under my plan in any circumstance, and what documentation would that take?
6. What are the deadlines for a formulary exception, an internal appeal and an external review under my plan?

Ask for each answer in writing or by secure message. A verbal yes from a call center is not a coverage determination, and a written one is what an appeal is built from. For the brand side numbers to compare against, see /blog/how-much-does-wegovy-cost. If you want to ask a person rather than read further, /help is the place to start.

Covered and cheaper are two different questions

Here is the point most coverage articles skip. Covered does not mean cheap, and not covered does not mean expensive.

When a plan puts an approved product on a high tier, or applies a deductible, or excludes the category, your real cost for the brand can be large even though the drug is technically on the list. The honest comparison is not a hypothetical low copay against a cash price. It is your actual, documented out-of-pocket cost after deductible, coinsurance and prior authorization, against the published all-in cash price of the alternative you are considering. You can only run that comparison once you have the written answers from the six questions above.

And the honest closing statement: for compounded preparations, cash is what most patients pay. They sit outside the payment system described in this article, so there is usually no copay to compare, no deductible to meet and no formulary tier to argue about. A health savings account or flexible spending account card is the most common way a dollar with any plan or tax connection touches a compounded prescription at all, and that is a tax treatment, not coverage. Anyone weighing the two routes should decide with a licensed physician who can see the full medical history and the plan documents together. Two companion pages carry the parts this one summarizes: what Medicare covers for the approved products and what Medicaid does about compounded GLP-1. The help center explains any term here that is unfamiliar.

This article is for informational purposes only and does not constitute medical advice. Compounded medications are not FDA-approved as final products. Compounded preparations are prescribed by US-licensed physicians and prepared by state-licensed compounding pharmacies. Medication is prescribed only if a licensed physician determines it is appropriate. Individual results may vary.

Telehealth prescribing rules differ by state. Read the state-by-state guide.